- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01977443
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
November 1, 2016 updated by: Adenovir Pharma AB
Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 12200
- Augenklinik Universitätzmedizin Charité
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf
-
Freiburg, Germany, 79106
- Universitäts-Augenklinik Freiburg
-
Köln, Germany, 51109
- Augenklinik Köln, Merheim
-
Lübeck, Germany, 23538
- Universitäts-klinikum Schleswig-Holstein
-
Tübingen, Germany, 72026
- Augenklinik, Universitätsklinikum Tübingen
-
Würzburg, Germany, 97080
- Universitäts-Augenklinik
-
-
-
-
-
Katowice, Poland, 40-514
- Katowice University Hospital
-
Tarnow, Poland, 33-100
- P. Oleksy Centrum Medyczne Uno-Med
-
-
-
-
-
Stockholm, Sweden
- St Eriks Eye Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The patients have to meet all of the following criteria to be eligible to enter the study:
- Willing and able to provide informed consent.
- Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less 7 days at the time of giving informed consent.
- Using adequate contraceptive measures
Exclusion Criteria:
- Known or suspected allergy to any ingredient of the IMP or placebo.
- Symptoms correlating with EKC since more than 7 days.
- Diagnosis of other significant disease(s) than EKC in the eye.
- Diagnosis of bacterial or fungal ocular infections.
- Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study.
- Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion.
- Use of antiviral medications within 7 days prior to inclusion.
- Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes.
- Usage of any medication or herbal medicinal product for ocular administration at inclusion.
- Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period.
- Known or suspected drug abuse.
- Usage of contact lenses during the study.
- Participation in any other interventional clinical study within 30 days prior to inclusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: APD-209 Eye drops
|
|
Placebo Comparator: APD-209 Placebo Eye drops
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo.
Time Frame: 14 days
|
Viral load in tear liquid from EKC infected eyes, as measured by the area under the curve (AUC) at 3-14 days from start of treatment.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo.
Time Frame: 14 days
|
The time point of viral eradication in tear liquid from EKC infected eyes, defined as the time Point when viral load=0 or below the lower limit of quantification (LLOQ).
|
14 days
|
Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.
Time Frame: 14 days
|
Resolution of acute ocular symptoms at each time of assessment, as measured by objective (Investigator-based) assessment of conjunctival discharge and redness.
|
14 days
|
Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.
Time Frame: 14 days
|
Presence and location of opacities at each time of assessment, as measured by slit lamp examination.
|
14 days
|
Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.
Time Frame: 28 days
|
Visual acuity at each time of assessment by use of the logarithm of the Minimum Angle of Resolution (LogMAR) chart.
|
28 days
|
Assess the frequency of second eye infections.
Time Frame: 14 days
|
Occurrence of second eye infection.
|
14 days
|
Assess the safety and tolerability of APD-209 Eye drops.
Time Frame: 14 days
|
Safety variables: adverse events (AEs) (nature and incidence), Physical examination, vital signs, laboratory safety assessments (haematology, clinical chemistry and urinalysis)
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Carl Gustaf Laurell, MD PhD, St Eriks Eye Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
October 31, 2013
First Submitted That Met QC Criteria
November 5, 2013
First Posted (Estimate)
November 6, 2013
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012/ADE002
- 2012-005694-31 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viral Conjunctivitis
-
ShireCompletedAcute Viral ConjunctivitisUnited States, Brazil
-
University of MiamiNovaBay Pharmaceuticals, Inc.Terminated
-
University of Campinas, BrazilCompletedViral ConjunctivitisBrazil
-
NicOxCompleted
-
Mahidol UniversityCompleted
-
Federal University of São PauloCompletedAdenoviridae Infections | Conjunctivitis, ViralBrazil
Clinical Trials on APD-209 Eye drops
-
Hai Yen Eye CareBrien Holden Vision InstituteCompleted
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Recruiting
-
Medical University of ViennaCompleted
-
Alcon ResearchCompleted
-
AllerganCompletedDry Eye SyndromesUnited States
-
Alcon ResearchCompletedDry EyeUnited States
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedCorneal Epithelial DefectChina